Brought to you by 
Series B brings in $22mm for iPierian; raises another $6mm
09 Sep 2010
Executive Summary
Three-year-old iPierian Inc. (uses induced pluripotent stem cells in its drug discovery efforts) raised $22mm in its Series B financing round led by first-time backer Google Ventures, which adds a board member. Other new investors Mitsubishi UFJ Capital and ATEL Ventures were joined by returning shareholders Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital, and FinTech Global Capital. Concurrent with the round, the company has named Michael C. Venuti, PhD as its new CEO and board member.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B brings in $22mm for iPierian; raises another $6mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice